Dr. Joseph Rubinfeld, Ph.D. served as the Chief Scientific Advisor of Generex Biotechnology Corp. since August 2009. Dr. Rubinfeld founded JJ Pharma, Inc., in April 2004 and served as its Chairman and Chief Executive Officer. Dr. Rubinfeld has been the Chief Scientific Advisor of CytRx Corporation since December 2008. He co-founded Astex Pharmaceuticals, Inc. (a/k/a SuperGen Inc.) in 1991 and served as its Chairman Emeritus from January 2004 to February 8, 2005, Chief Executive Officer and President from 1991 to December 31, 2003, Chief Scientific Officer from 1991 to September 1997 and also served as its Chairman. He served as the Chief Executive Officer and President of Cytrx Corporation since its inception and was Chief Scientific Officer since its inception until September 1997. He has a fifty year history in pharmaceutical and consumer product development. Dr. Rubinfeld also co-founded the IBA (Industrial Biotechnology Association) in 1981. Dr. Rubinfeld was one of the four initial founders of Amgen Inc. in 1980 and served as Vice President and Chief of Operations until 1983. From 1987 to 1990, he served as Senior Director of Cetus Corporation. From 1968 to 1980, he was employed at Bristol-Myers Company International Division ("Bristol-Myers") in a variety of positions, served as Vice President and Director of Research and Development. While at Bristol-Myers, Dr. Rubinfeld was instrumental in licensing the original anticancer line of products for Bristol-Myers, including mitomycin and bleomycin. He was a research scientist with several pharmaceutical and consumer product companies including Schering-Plough Corporation and Colgate-Palmolive Co. He serves as the Vice Chairman of the Board of Directors of Quark Biotech, Inc. He served as Vice Chairman of the Board at Quark Pharmaceuticals, Inc. He serves as Director of NeoTherapeutics, Inc. and BioLuminate, Inc. He has been a Director of Regenicin, Inc. since August 2010. Dr. Rubinfeld has been an Independent Director of Cytrx Corporation since July 2002 and serves as its Member of Scientific Advisory Board. He has been a Member of Advisory Board at Amarantus BioSciences, Inc., since November 2012. He served as a Director of SuperGen Inc. from 1991 to March 2005. He served as a Director of Sarepta Therapeutics, Inc., from 1996 to March 2004. He served as Member of Scientific Advisory Board of AVI BioPharma Inc. in the area of Oncology and also served as its Director from 1996 to March 2004. Dr. Rubinfeld has numerous patents and/or publications on a wide range of inventions and developments including the 10-second developer for Polaroid film, manufacture of cephalosporins, and the first commercial synthetic biodegradable detergent. In 1984, he received the Common Wealth Award for Invention. Dr. Rubinfeld received his BS in Chemistry from City College of New York, and his M.A. and Ph.D. in Chemistry from Columbia University.
Collapse Detail
Corporate Headquarters*
11726 San Vicente Boulevard
Los Angeles, California 90049
United States
Phone: 310-826-5648
Fax: 310-826-6139
Board Members Memberships*
Former Vice Chairman and Member of Compensation Committee
Quark Pharmaceuticals, Inc.
Director
BioLuminate, Inc.
Founder
JJ Pharma, Inc.
1991-2005
Former Chairman Emeritus and Chief Scientist
Astex Pharmaceuticals, Inc.
1996-2004
Former Member of Scientific Advisory Committee
Sarepta Therapeutics, Inc.
2002-Present
Chief Scientific Advisor, Independent Director, Member of Scientific Advisory Board, Chairman of Compensation Committee and Member of Audit Committee
CytRx Corporation
2010-Present
Director
Regenicin, Inc.
Education*
MA
Columbia University
PhD
Columbia University
BS
The City College of New York
Other Affiliations*
Astex Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc.
Generex Biotechnology Corp.
Quark Pharmaceuticals, Inc.
Columbia University
The City College of New York
BioLuminate, Inc.
JJ Pharma, Inc.
Regenicin, Inc.
Amarantus BioSciences, Inc.
Annual Compensation*
There is no Annual Compensation data available.
Stock Options*
There is no Stock Options data available.
Total Compensation*
Total Annual Cash Compensation $49,250
Total Calculated Compensation $75,700
News 
Market Data 
Discover 
AI
